Shuo Liu
About Shuo Liu
Shuo Liu is a Senior Research Investigator-Clinical Biomarker at BeiGene in Shanghai, China, with extensive experience in biomarker support for oncology clinical studies and expertise in gene knockout technologies.
Company
Shuo Liu currently works at BeiGene as a Senior Research Investigator-Clinical Biomarker based in Shanghai, China. BeiGene is a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. In his role, Shuo provides biomarker support for both early and late-stage oncology clinical studies and actively collaborates with clinical study and translational research teams.
Title
Shuo Liu holds the title of Senior Research Investigator-Clinical Biomarker. His responsibilities include supporting RP2D determination from a pharmacodynamic biomarker perspective in phase 1 trials and managing biomarker operations such as budget making, contract preparation, and sample management.
Education and Expertise
Shuo Liu achieved a Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology from Wuhan University, a Master of Science (M.S.) in Cell Biology from Wuhan University, and a Bachelor's degree in Resources and Environment from Northeast Agricultural University. He has expertise in gene knockout in cells or rodents using CRISPR or TALEN technology, developing cell-based assays, and establishing animal models for research purposes.
Background
Shuo Liu has extensive experience in the pharmaceutical and biotechnology sectors. He previously worked at The Janssen Pharmaceutical Companies of Johnson & Johnson as Scientist 4, at BioDuro as Senior Scientist I, at Amgen as Senior Associate/Postdoc Research Fellow, and at Wuhan University as Experiment Tutor. Throughout his career, he has led internal and external cross-functional teams to manage and execute diagnostic development partnerships.
Achievements
In his career, Shuo Liu has made significant contributions by developing cell-based assays and establishing animal models, as well as providing biomarker support for oncology clinical studies. He has played a crucial role in RP2D determination from a pharmacodynamic biomarker perspective in phase 1 trials and collaborated with clinical study and translational research teams to address scientific questions related to drug targets and predictive biomarkers.